Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1275)	5/13/2003 9:49:52 AM
From: Ian@SI	Respond to of 1321

Erik, I don't know the answer to your question. Visudyne, destroys the abnormal blood vessels which cause the scarring of the macula. It does this without any damage done to the retina or other parts of the eye. Others have tried unsuccessfully to come up with a product with a recent failure being PHA/MRVT's SnET2 trial. To my knowledge, Visudyne doesn't prevent vision loss in all cases, it slows progression of AMD. I wouldn't be surprised to see a combination of treatments ultimately being required to arrest this devastating disease. FWIW, Ian